Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. 2021

Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
Department of Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein Lübeck, Lübeck, Germany.

Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and for the control of ongoing inflammation and autoimmunity. The cytokine interleukin-2 (IL-2) is essentially required for the growth and survival of Treg in the peripheral lymphatic tissues and thus plays a vital role in the biology of Treg. Most autoimmune and rheumatic diseases exhibit disturbances in Treg biology either at a numerical or functional level resulting in an imbalance between protective and pathogenic immune cells. In addition, in some autoimmune diseases, a relative deficiency of IL-2 develops during disease pathogenesis leading to a disturbance of Treg homeostasis, which further amplifies the vicious cycle of tolerance breach and chronic inflammation. Low-dose IL-2 therapy aims either to compensate for this IL-2 deficiency to restore a physiological state or to strengthen the Treg population in order to be more effective in counter-regulating inflammation while avoiding global immunosuppression. Here we highlight key findings and summarize recent advances in the clinical translation of low-dose IL-2 therapy for the treatment of autoimmune and rheumatic diseases.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D012216 Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement. Rheumatism,Disease, Rheumatic,Diseases, Rheumatic,Rheumatic Disease
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D050378 T-Lymphocytes, Regulatory CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells. Regulatory T Cell,Regulatory T-Cell,Regulatory T-Lymphocyte,Regulatory T-Lymphocytes,Suppressor T-Lymphocytes, Naturally-Occurring,T-Cells, Regulatory,Th3 Cells,Tr1 Cell,Treg Cell,Regulatory T-Cells,Suppressor T-Cells, Naturally-Occurring,Tr1 Cells,Treg Cells,Cell, Regulatory T,Cell, Th3,Cell, Tr1,Cell, Treg,Cells, Regulatory T,Cells, Th3,Cells, Tr1,Cells, Treg,Naturally-Occurring Suppressor T-Cell,Naturally-Occurring Suppressor T-Cells,Naturally-Occurring Suppressor T-Lymphocyte,Naturally-Occurring Suppressor T-Lymphocytes,Regulatory T Cells,Regulatory T Lymphocyte,Regulatory T Lymphocytes,Suppressor T Cells, Naturally Occurring,Suppressor T Lymphocytes, Naturally Occurring,Suppressor T-Cell, Naturally-Occurring,Suppressor T-Lymphocyte, Naturally-Occurring,T Cell, Regulatory,T Cells, Regulatory,T Lymphocytes, Regulatory,T-Cell, Naturally-Occurring Suppressor,T-Cells, Naturally-Occurring Suppressor,T-Lymphocyte, Regulatory,Th3 Cell
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
January 2019, Nature reviews. Rheumatology,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
May 2024, International reviews of immunology,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
December 2019, Journal of immunology (Baltimore, Md. : 1950),
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
September 2022, Clinical and experimental rheumatology,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
January 2023, Science bulletin,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
May 1999, Hepato-gastroenterology,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
February 2024, Rheumatology and therapy,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
May 2015, Nature reviews. Immunology,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
December 2005, Reumatologia clinica,
Hanna Graßhoff, and Sara Comdühr, and Luisa R Monne, and Antje Müller, and Peter Lamprecht, and Gabriela Riemekasten, and Jens Y Humrich
February 1999, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!